Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 222,884,459 papers from all fields of science
Search
Sign In
Create Free Account
Lipoatrophy
Localized loss of fat tissue. [HPO:sdoelken]
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Lipodystrophy
Penttinen-Aula syndrome
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study
T. Piloya
,
S. Bakeera-Kitaka
,
A. Kekitiinwa
,
M. Kamya
Journal of the International AIDS Society
2012
Corpus ID: 17207349
With widespread use of antiretroviral therapy (ART) and prolonged survival of HIV‐infected children, toxicities like…
Expand
Highly Cited
2010
Highly Cited
2010
Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda.
J. van Griensven
,
R. Zachariah
,
F. Rasschaert
,
Jules Mugabo
,
Edi F. Atté
,
T. Reid
Transactions of the Royal Society of Tropical…
2010
Corpus ID: 14857820
Highly Cited
2008
Highly Cited
2008
Improvements in Subcutaneous Fat, Lipid Profile, and Parameters of Mitochondrial Toxicity in Patients with Peripheral Lipoatrophy When Stavudine is Switched to Tenofovir (LIPOTEST Study)
E. Ribera
,
J. C. Paradiñeiro
,
+13 authors
A. Pahissa
HIV Clinical Trials
2008
Corpus ID: 23134417
Abstract Background: Lipoatrophy is the most stigmatizing side effect of stavudine therapy. We assessed the long-term effects of…
Expand
Review
2007
Review
2007
Long‐term complications of antiretroviral therapy: lipoatrophy
L. Waters
,
M. Nelson
International journal of clinical practice
2007
Corpus ID: 33569023
The effective use of potent antiretroviral therapy has dramatically improved the life expectancy for HIV‐infected individuals…
Expand
Review
2005
Review
2005
Comparison of Three Different Interventions for the Correction of HIV-Associated Facial Lipoatrophy: A Prospective Study
G. Guaraldi
,
G. Orlando
,
+8 authors
R. Espósito
Antiviral Therapy
2005
Corpus ID: 19961035
Objective To compare autologous fat transfer (AFT), injections of reabsorbable [polylactic acid (PLA)] and non-reabsorbable…
Expand
2005
2005
Insulin resistance and clinical aspects of non-alcoholic steatohepatitis (NASH).
Naresh Agarwal
,
B. Sharma
Hepatology Research
2005
Corpus ID: 42632192
Review
2004
Review
2004
HIV-related lipodystrophy and related factors.
A. Tershakovec
,
I. Frank
,
Daniel Rader
Atherosclerosis
2004
Corpus ID: 1675198
Highly Cited
2003
Highly Cited
2003
A 48‐Week, Randomized, Open‐Label Comparison of Three Abacavir‐Based Substitution Approaches in the Management of Dyslipidemia and Peripheral Lipoatrophy
Moyle Gj
,
C. Baldwin
,
B. Langroudi
,
S. Mandalia
,
B. Gazzard
Journal of Acquired Immune Deficiency Syndromes
2003
Corpus ID: 21242123
Background: The mechanisms by which dyslipidemia and lipoatrophy develop during antiretroviral therapy are not clear. No…
Expand
Highly Cited
2002
Highly Cited
2002
Analysis of the mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with or without lipoatrophy
G. McComsey
,
D. Tan
,
M. Lederman
,
E. Wilson
,
L. Wong
AIDS (London)
2002
Corpus ID: 20905714
Objective To investigate the molecular mechanisms of nucleoside analogue reverse transcriptase inhibitor (NRTI)-associated…
Expand
Highly Cited
2001
Highly Cited
2001
The prevalence of lipodystrophy in an ambulant HIV‐infected population: it all depends on the definition
V. Carter
,
J. Hoy
,
Michael Bailey
,
P. Colman
,
I. Nyulasi
,
A. Mijch
HIV Medicine
2001
Corpus ID: 46203980
Objectives This study's objective was to determine the prevalence of body shape changes and metabolic abnormalities in an…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE